Skip To Main Content

Cevostamab (FcRH5 x CD3)

(RG6160)

Hematology

Phase I

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)

NCT04910568

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

NCT03275103